News publication
Everything we hold that Biotech Dispatch published.
Every article we hold from Biotech Dispatch.
Regulators have favourably answered most of the biotech's questions ahead of a planned mid-stage stem cell therapy trial, with one manufacturing concern still to resolve before the study can start.
Wearable sensor maker dorsaVi has raised $3 million via a share placement to grow its movement data library for humanoid robotics developers and advance its neuromorphic and semiconductor chip programs.
Under Dealroom ·leads this story in the feed
Neurizon Therapeutics appoints Chris Bremer as CEO while interim executive chairman Sergio Duchini becomes non-executive chairman, with the company's ALS drug awaiting Phase 2/3 trial results in 2027.
Melbourne biotech Paradigm Biopharmaceuticals appointed FTI Consulting administrators after its Phase 3 trial failed an interim efficacy threshold, and now seeks to restructure debts via a deed of company arrangement.
Telix Pharmaceuticals has agreed to merge with German isotope producer ITM in a US$1.65 billion upfront deal, with contingent payments of up to US$700 million, creating a combined radiopharmaceutical group.
Under Business News Australia ·leads this story in the feed
Biotech Paradigm Biopharmaceuticals appoints rheumatology specialist Daniel Furtner as chief medical officer; predecessor Donna Skerrett stays as senior scientific advisor, and the firm's late-stage osteoarthritis trial has finished enrolling 538 participants.
Telix Pharmaceuticals has gained US regulatory clearance for its glioma imaging agent Pixclara, a world first, and is now studying the compound in late-stage trials for brain metastases.
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.
OncoSil Medical says a Madrid hospital has treated its 100th Spanish pancreatic cancer patient with its brachytherapy device, as the ASX-listed company focuses on deepening use across its 11 treatment sites.
OncoSil Medical has raised $5.6m from three large existing shareholders to fund overseas and domestic launches of its radiation therapy, after winning TGA and FDA clearances for pancreatic and bile duct cancer use.
Neurizon Therapeutics, a Melbourne biotech developing an ALS treatment, has appointed industry veteran Dr Chris Bremer as CEO as its lead drug NUZ-001 heads toward Phase 2/3 trial results in 2027.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Melbourne biotech ENA Respiratory has received $2.98 million from incubator Biointelect Venturer's first investment round, one of six companies backed, funding a Phase Ib asthma study of its INNA-051 antiviral nasal spray.
Under Brandon Capital portfolio ·leads this story in the feed
Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.
Alterity Therapeutics has appointed MST Financial Services to backstop its expiring listed options ahead of a pivotal Phase 3 trial of its lead drug candidate for a rare neurodegenerative disorder.
Mesoblast's yearly report shows revenue leaping on first-year American sales of Ryoncil, losses narrowing, and a US$125 million debt refinancing, with its spinal disc trial fully recruited ahead of 2027 data.
Entropy Neurodynamics has agreed with UCSF to run a US Phase 2 trial of its psilocin drug TRP-8803 against escitalopram in young adults with depression, pending FDA clearance, with Swinburne and BioCina supporting.
Melbourne biotech Starpharma grew annual revenue on a Genentech licence payment, cut its loss, and completed a $30 million entitlement offer, giving it cash into 2028 to advance its cancer pipeline.
The two diagnostics companies have entered early-stage merger talks aiming to combine rapid pathogen testing with gut microbiome analysis, though both stress the discussions are preliminary with no terms agreed.
European regulators have cleared Neuren's Rett syndrome drug DAYBU, the first such treatment authorised in the EU, with milestone payments due to the Melbourne biotech from licence partner Acadia.
Acrux has hired Dr Jolanta Airey as chief medical officer, adding clinical leadership as the company prepares late-stage trials in the United States for its women's testosterone therapy.
Avecho Biotechnology brings in a former CSL dealmaking executive as a consultant to help license its Phase 3 CBD insomnia capsule internationally.
Mesoblast has finished dosing all 350 patients in its phase 3 trial of rexlemestrocel-L for degenerative disc disease, with data due mid-2027 and a possible US biologics application to follow.
Australian device maker OncoSil Medical has won US FDA humanitarian exemption approval for its targeted radiation treatment for unresectable distal bile duct cancer, opening a path to American commercialisation in financial year 2027.
Sydney biotech Biotron reports lab results showing its hepatitis B drug candidate works against HBV and HDV, and will begin formal preclinical studies ahead of planned human trials in 2027.
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
Starpharma wrapped up its $32 million shareholder rights issue with roughly 99% participation, with proceeds earmarked for first-in-human testing of its DEP HER2-Lutetium cancer therapy.
Under kalkine.com.au ·leads this story in the feed
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
Starpharma has launched a shareholder entitlement offer of about A$32 million, underwritten by Canaccord Genuity, to fund a Phase 1 cancer study and broaden its dendrimer oncology pipeline.
Under kalkine.com.au ·leads this story in the feed
Adelaide medtech Ferronova added $6 million to its Series A for image-guided cancer surgery, led by Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian and Renew Pharmaceuticals; Renew's parent UltraGreen.ai recently listed in Singapore.
Under Uniseed ·leads this story in the feed
Deals recorded from Biotech Dispatch's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| dorsaVi | Unnamed stage | 6 Oct 2026 | $3m | |
| Neurizon Therapeutics Limited | Grant | 9 Sep 2026 | - | |
| ENA Respiratory | Grant | 1 Sep 2026 | $3m | |
| Percheron Therapeutics | Unnamed stage | 31 Aug 2026 | $2.3m | |
| AdaptiVax | Accelerator | 30 Aug 2026 | - | |
| Proboxis Biotechnology | Accelerator | 30 Aug 2026 | $1.5m | |
| Ebivanta Therapeutics | Accelerator | 30 Aug 2026 | $1.5m | |
| Saccharide Therapeutics | Accelerator | 30 Aug 2026 | - | |
| SAMMvax | Accelerator | 30 Aug 2026 | - | |
| ENA Respiratory | Accelerator | 30 Aug 2026 | $8.3m | |
| Starpharma | Unnamed stage | 4 Aug 2026 | $32m | |
| Ferronova | Series A | 17 Dec 2025 | $6m |
Companies named in Biotech Dispatch's articles, most-covered first.
Investors named in Biotech Dispatch's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Biointelect Venturer | 2 | |
| National Institutes of Health | 2 | |
| Artesian VC | Alternative asset management for debt and venture capital | 1 |
| Canaccord Genuity Australia | 1 | |
| Regal Partners | 1 | |
| Renew Pharmaceuticals | 1 | |
| South Australian Venture Capital Fund | 1 | |
| Uniseed/UniSuper | 1 |